Tempestade de citocinas no COVID-19: efeitos sistêmicos da desregulação imune
DOI:
https://doi.org/10.34119/bjhrv6n1-247Keywords:
citocinas, alterações fisiopatológicas, hiperativaçãoAbstract
A infecção pelo Sars-Cov-2 possui impacto mundial por se tratar de uma doença que pode apresentar quadros graves e até mesmo fatais. Seu caráter crítico é decorrente de uma tempestade de citocinas que se propaga no organismo, ou seja, uma desregulação do sistema imunológico que afeta diferentes órgãos, comprometendo-os. Todo esse processo envolve diferentes citocinas inflamatórias (IL-6, IL-2R, IL-8, TNF-alfa, fator estimulador da colônia de granulócitos etc.) e suas respectivas vias de sinalização, destacando-se a via da IL-6, a qual apresenta relação direta com a gravidade da doença. O método utilizado para a realização desse projeto foi uma revisão bibliográfica sistemática, com informações atualizadas e estudos recentes acerca do assunto, por meio de pesquisas na base de dados eletrônica Pubmed/MedLine (US National Libraryof Medicine); Google acadêmico (SCHOLAR); Portal Capes. A revisão evidenciou que inúmeros fatores estão associados ao processo inflamatório da doença, que dependem não apenas do patógeno, mas também do organismo acometido, de modo que o curso infeccioso se divide em diferentes estágios e a tempestade de citocinas é o evento responsável pelo agravamento da doença e acometimentos sistêmicos.
References
ABBAS, Abul et al. Imunologia celular e molecular. 9. ed. Rio de Janeiro: Elsevier, 2019.
ANTONIO, Maria Vitória do Nascimento et al. Tempestade de citocinas na COVID-19. Ulakes Journal Of Medicine, São Paulo, p. 31-40, 2020.
AZKUR, Ahmet Kursat et al. Immune response to SARS‐CoV‐2 and mechanisms of immunopathological changes in COVID‐19. Allergy, [S.L.], v. 75, n. 7, p. 1564-1581, jul. 2020. Wiley. http://dx.doi.org/10.1111/all.14364.
BEHRENS, Edward M. et al. Review: cytokine storm syndrome. Arthritis & Rheumatology, [S.L.], v. 69, n. 6, p. 1135-1143, 30 maio 2017. Wiley. http://dx.doi.org/10.1002/art.40071.
BHASKAR, Sonu et al. Cytokine Storm in COVID-19—Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: the reprogram consortium position paper. Frontiers In Immunology, [S.L.], v. 11, n. 1, p. 1-2, 10 jul. 2020. Frontiers Media SA. http://dx.doi.org/10.3389/fimmu.2020.01648
BRITO, Wallery Glleysianne Ferreira; SILVA, João Pedro Dantas Oliveira. Impactos neuropatológicos do COVID-19. Brazilian Journal Of Health Review, [S.L.], v. 3, n. 3, p. 4227-4235, maio 2020. Brazilian Journal of Health Review. http://dx.doi.org/10.34119/bjhrv3n3-026.
CHEN, Guang et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. Journal Of Clinical Investigation, [S.L.], v. 130, n. 5, p. 2620-2629, 13 abr. 2020. American Society for Clinical Investigation. http://dx.doi.org/10.1172/jci137244.
FAJGENBAUM, David C. et al. Cytokine Storm. New England Journal Of Medicine, [S.L.], v. 383, n. 23, p. 2255-2273, 3 dez. 2020. Massachusetts Medical Society. http://dx.doi.org/10.1056/nejmra2026131.
FARA, Antonella et al. Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines. Open Biology, [S.L.], v. 10, n. 9, p. 200160, set. 2020. The Royal Society. http://dx.doi.org/10.1098/rsob.200160.
GUO, Yan-Rong et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Military Medical Research, [S.L.], v. 7, n. 1, 13 mar. 2020. Springer Science and Business Media LLC. http://dx.doi.org/10.1186/s40779-020-00240-0.
HU, Biying et al. The cytokine storm and COVID‐19. Journal Of Medical Virology, [S.L.], v. 93, n. 1, p. 250-256, 30 set. 2020. Wiley. http://dx.doi.org/10.1002/jmv.26232.
JOHNS HOPKINS UNIVERSITY AND MEDICINE (Estados Unidos). Coronavirus Resource Centre. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. 2021. Disponível em: https://coronavirus.jhu.edu/map.html. Acesso em: 18 abr. 2021.
LIU, Tao et al. The potential role of IL-6 in monitoring severe case of coronavirus disease 2019. Medrxiv- The Preprint Server For Health Sciences, [S.L.]. 6 mar. 2020. Cold Spring Harbor Laboratory. http://dx.doi.org/10.1101/2020.03.01.20029769.
NAJJAR, Souhel et al. Central nervous system complications associated with SARS-CoV-2 infection: integrative concepts of pathophysiology and case reports. Journal Of Neuroinflammation, [S.L.], v. 17. 6 ago. 2020. Springer Science and Business Media LLC. http://dx.doi.org/10.1186/s12974-020-01896-0.
NASCIMENTO, Jorge Henrique Paiter et al. COVID-19 e Estado de Hipercoagulabilidade: uma nova perspectiva terapêutica. Arquivos Brasileiros de Cardiologia, [S.L.], v. 114, n. 5, p. 829-833, maio 2020. Sociedade Brasileira de Cardiologia. http://dx.doi.org/10.36660/abc.20200308
PALUDAN, Søren R. et al. Innate immunological pathways in COVID-19 pathogenesis. Science Immunology, [S.L.], v. 7, n. 67, 7 jan. 2022. American Association for the Advancement of Science (AAAS). http://dx.doi.org/10.1126/sciimmunol.abm5505.
PASCOAL, David Balbino et al. Síndrome Respiratória Aguda: uma resposta imunológica exacerbada ao covid19. Brazilian Journal Of Health Review, [S.L.], v. 3, n. 2, p. 2978-2994, abr. 2020. Brazilian Journal of Health Review. http://dx.doi.org/10.34119/bjhrv3n2-138.
PEDERSEN, Savannah F. et al. SARS-CoV-2: a storm is raging. Journal Of Clinical Investigation, [S.L.], v. 130, n. 5, p. 2202-2205, 13 abr. 2020. American Society for Clinical Investigation. http://dx.doi.org/10.1172/jci137647.
RAGAB, Dina et al. The COVID-19 Cytokine Storm; What We Know So Far. Frontiers In Immunology, [S.L.], v. 11, 16 jun. 2020. Frontiers Media SA. http://dx.doi.org/10.3389/fimmu.2020.01446.
REZA, Nosheen et al. Secondary Impact of the COVID-19 Pandemic on Patients With Heart Failure. Circulation: Heart Failure, [S.L.], v. 13, n. 5, maio 2020. Ovid Technologies (Wolters Kluwer Health). http://dx.doi.org/10.1161/circheartfailure.120.007219.
ROBBA, Chiara et al. Multiple organ dysfunction in SARS-CoV-2: mods-cov-2. Expert Review Of Respiratory Medicine, [S.L.], v. 14, n. 9, p. 865-868, 22 jun. 2020. Informa UK Limited. http://dx.doi.org/10.1080/17476348.2020.1778470.
SCHULERT, Grant S. et al. Pathogenesis of Macrophage Activation Syndrome and Potential for Cytokine- Directed Therapies. Annual Review Of Medicine, [S.L.], v. 66, n. 1, p. 145-159, 14 jan. 2015. Annual Reviews. http://dx.doi.org/10.1146/annurev-med-061813-012806.
SIDDIQI, Hasan K. et al. COVID-19 illness in native and immunosuppressed states: a clinical⠳therapeutic staging proposal. The Journal Of Heart And Lung Transplantation, [S.L.], v. 39, n. 5, p. 405-407, maio 2020. Elsevier BV. http://dx.doi.org/10.1016/j.healun.2020.03.012.
SORDI, Luiz Henrique Silva de et al. O Papel da Imunidade Inata na COVID-19. Revista Ciências em Saúde, [S.L.], v. 10, n. 3, p. 5-8, 2 jul. 2020. Revista Ciencias em Saude. http://dx.doi.org/10.21876/rcshci.v10i3.997.
SUN, Xinjuan et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine & Growth Factor Reviews, [S.L.], v. 53, p. 38-42, jun. 2020. Elsevier BV. http://dx.doi.org/10.1016/j.cytogfr.2020.04.002.
TAN, Li et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduction And Targeted Therapy, [S.L.], v. 5, n. 1, 27 mar. 2020. Springer Science and Business Media LLC. http://dx.doi.org/10.1038/s41392-020-0148-4.
WAUTERS, Els et al. Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages. Cell Research, [S.L.], v. 31, n. 3, p. 272-290, 21 jan. 2021. Springer Science and Business Media LLC. http://dx.doi.org/10.1038/s41422-020-00455-9.
XAVIER, Analucia R. et al. COVID-19: clinical and laboratory manifestations in novel coronavirus infection. Jornal Brasileiro de Patologia e Medicina Laboratorial, [S.L.], jun. 2020. GN1 Genesis Network. http://dx.doi.org/10.5935/1676-2444.20200049.
ZANZA, Christian et al. Cytokine Storm in COVID-19: immunopathogenesis and therapy. Medicina, [S.L.], v. 58, n. 2, p. 144, 18 jan. 2022. MDPI AG. http://dx.doi.org/10.3390/medicina58020144.
ZHANG, Chi et al. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. International Journal Of Antimicrobial Agents, [S.L.], v. 55, n. 5, p. 105954, maio 2020. Elsevier BV. http://dx.doi.org/10.1016/j.ijantimicag.2020.105954.
ZUO, Yu et al. Neutrophil extracellular traps in COVID-19. Jci Insight, [S.L.], 24 abr. 2020. American Society for Clinical Investigation. http://dx.doi.org/10.1172/jci.insight.138999.
